Navigation Links
3SBio Inc. Announces Extraordinary General Meeting of Shareholders
Date:3/24/2013

merger.

Shareholders of record as of the close of business in the Cayman Islands on April 12, 2013 will be entitled to vote at the EGM.  The record date for ADS holders entitled to instruct JPMorgan Chase Bank, N.A., the ADS depositary, to vote the shares represented by the ADSs is the close of business in New York City on March 25, 2013.  Additional information regarding the EGM and the Merger Agreement can be found in the Transaction Statement on Schedule 13E-3, and the proxy statement attached as Exhibit (a)-(1) thereto, filed with the Securities and Exchange Commission (the "SEC"), which can be obtained from the SEC's website (http://www.sec.gov).

INVESTORS AND SHAREHOLDERS ARE URGED TO READ CAREFULLY AND IN THEIR ENTIRETY THESE MATERIALS AND OTHER MATERIALS FILED WITH OR FURNISHED TO THE SEC, AS THEY CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY, THE PROPOSED MERGER AND RELATED MATTERS.

This announcement is neither a solicitation of proxy, an offer to purchase nor a solicitation of an offer to sell any securities and it is not a substitute for any proxy statement or other filings that have been or will be made with the SEC.

About 3SBio Inc.

3SBio is a leading, fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China.  Its focus is on addressing large markets with significant unmet medical needs in nephrology, oncology, supportive cancer care, inflammation and infectious diseases.  With headquarters and GMP-certified manufacturing facilities in Shenyang, PRC, 3SBio employs over 800 people.  Shares trade in the form of ADSs on the NASDAQ global market under the ticker symbol "SSRX".  Please see www.3SBio.com for more information.

For investor
'/>"/>

SOURCE 3SBio Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. 3SBio Inc. Schedules Unaudited First Quarter 2012 Results
2. 3SBio Inc. To Present at the DB Access Asia Conference 2012
3. 3SBio Obtains SFDA Approval to Join Global Phase III Trial for Voclosporin
4. 3SBio Inc. Schedules Unaudited Second Quarter 2012 Results
5. 3SBio Inc. Announces Changes to Its Board of Directors
6. Apexigen Announces the Filing of an IND by its Partner, 3SBio
7. 3SBio Inc. to Hold 2012 Annual General Meeting on October 10, 2012
8. 3SBio Inc. Announces Receipt of "Going Private" Proposal at $15 Per ADS
9. 3SBio Independent Committee Selects Legal Counsel in connection with Going Private Proposal
10. 3SBio Inc. Announces Unaudited Third Quarter 2012 Results
11. 3SBio Inc. Schedules Unaudited Fourth Quarter and Full Year 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... September 2, 2014   ... atrial muestran agentes antitrombóticos no utilizados óptimamente para ... -- Las presentaciones de GARFIELD-AF en el ESC ... y los resultados de pacientes en riesgo de ...    Los datos de casi 12.500 ...
(Date:9/2/2014)... September 2, 2014 ... ESC-Kongress 2014 präsentierte GARFIELD-AF-Register bietet einen ... von schlaganfallgefährdeten Patienten in der klinischen ... Daten der nahezu 12.500 ... und unabhängigen Forschungsinitiative zur Untersuchung von ...
(Date:9/2/2014)... , September 2, 2014 ... CONGRESS 2014 provide insight into treatment and outcomes ... clinical practice --   Data from ... Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF), an innovative, ... prevention strategies for atrial fibrillation (AF) patients remain ...
Breaking Medicine Technology:Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 2Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 3Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 4Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 5Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 6Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 7Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 8Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 9Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 10Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 11Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 2Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 3Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 4Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 5Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 6Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 7Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 8Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 9Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 10Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 11Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 2Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 3Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 4Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 5Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 6Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 7Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 8Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 9
... /PRNewswire-USNewswire/ – CoMeD – On Friday, July ... (UNEP) distributed a revised text for its comprehensive ... were gratified to see pharmaceuticals listed in "Annex C ... The Coalition for Mercury-free Drugs (CoMeD) ...
... Reportlinker.com announces that a new market ... Sustained Release Injectables: Evolving ... http://www.reportlinker.com/p0581172/Sustained-Release-Injectables-Evolving-Formulations-Improving-Dosing-Regimens .html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication ... to increase the duration of efficacy for ...
Cached Medicine Technology:Global Mercury Treaty May Include Ban on Mercury in Medicine 2Global Mercury Treaty May Include Ban on Mercury in Medicine 3Sustained Release Injectables: Evolving Formulations, Improving Dosing Regimens 2Sustained Release Injectables: Evolving Formulations, Improving Dosing Regimens 3
(Date:9/2/2014)... Columbia, SC (PRWEB) September 02, 2014 The ... an outreach fair and public town hall meeting for Veterans ... be available at the outreach fair to provide Veterans with ... B. McMurry. “The town hall will provide a forum where ... our VA programs.” , The outreach fair will be held ...
(Date:9/2/2014)... early-stage breast cancer in California, the percentage undergoing a ... this procedure was not associated with a lower risk ... a study in the September 3 issue of ... the removal of one breast was associated with a ... in the study. , Randomized trials have demonstrated similar ...
(Date:9/2/2014)... Medex Analytic Services is delighted to announce the ... Fla. due to their greater than forecasted growth. , ... 2014 year by distinguishing Medex in the industry,” said ... level of service and professionalism in the delivery of ... has responded.” , The location of the new ...
(Date:9/2/2014)... TUESDAY, Sept. 2, 2014 (HealthDay News) -- Two new ... One suggests that 6-year-olds who were breast-fed have a ... to bottle-fed infants, while the other finds a similar ... upholds the "many benefits of breast-feeding in the immediate ... Lenox Hill Hospital in New York City. She was ...
(Date:9/2/2014)... Sept. 2, 2014 (HealthDay News) -- A leading group ... of the major form of advanced breast cancer. ... to drugs that target the HER2 protein, the American ... news release. Almost 80 percent of women ... noted. "In releasing this guideline, our aim is ...
Breaking Medicine News(10 mins):Health News:Increase seen in use of double mastectomy 2Health News:Increase seen in use of double mastectomy 3Health News:Medex Analytic Services Announces New Location for Corporate Headquarters 2Health News:More Evidence Breast-Feeding Lowers Child's Risk of Infections, Allergies 2Health News:New Guidelines for Treating Form of Advanced Breast Cancer 2
... An Indian who moderates an Internet forum on HIV/AIDS ... 16th International AIDS Conference here scheduled from Aug 13. ... delegates to build support for eliminating disparities in access ... a conference co-chair and director of the McGill University ...
... prowess in adding muscle to existing blackcurrants with a view ... reflect in nutritive fruit beverages. The Scottish Crop Research Institute ... manufactured in the blackcurrant bushes, so that they could look ... study costing about ?1.2m will endeavor to enhance the quality ...
... cancer cells after breast cancer surgery may play a crucial ... a new study published// in the August 1, 2006, issue ... Physics, the official journal of ASTRO, the American Society for ... 213,000 American women will learn they have breast cancer. Many ...
... pregnancy counselling Medicare item number may well breach women's ... ,Available only to women who are uncertain about whether ... identification of women who talk to their GP about ... would put on the record the fact that a ...
... Low calorie foods that are high in nutrition may be the ... fear of piling calories//. After studying the dietary details of about ... vegetables and grains were likely to consume a larger quantity of ... despite consuming a lot of food, their calorie count was much ...
... paying their price by breaking bones and spraining ankles. ... off their high-heeled sandals, causing several injuries. ... emergency unit at University Hospital of Wales, Cardiff, pointed ... ,He advised women to wear shoes with ...
Cached Medicine News:Health News:Indian to Conduct Workshop at Global AIDS Meet 2Health News:Leftover Cancer Cells May Dictate Breast Cancer Relapse 2Health News:Doctors Warn on Pregnancy Counselling 2
For the quantitative in vitro determination of Magnesium in serum, plasma and urine...
The LDH method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of lactate dehydrogenase activity in serum or plasma...
For the quantitative in vitro determination of Lactate Dehydrogenase (LD) in serum and plasma....
For the quantitative in vitro determination of Anti-Streptolysin-O (ASO) in serum....
Medicine Products: